MedTrace Logo

Effect of Rosuvastatin in Abdominal Sepsis

NCT00357123 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2011-02-21

No results posted yet for this study

Summary

The purpose of this study is to determine whether rosuvastatin is effective as a coadjuvant drug in the integral management of abdominal sepsis acknowledged by surgery.

Conditions

Interventions

DRUG

Rosuvastatin

20 mg 10 days daily since abdominal sepsis diagnosis

Sponsors & Collaborators

  • Universidad Autonoma de San Luis Potosí

    lead OTHER

Principal Investigators

  • Martin Sanchez-Aguilar, MSc · Experimental Surgery , Universidad Autonoma de San Luis Potosi

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-08-31
Primary Completion
2011-07-31
Completion
2011-09-30

Countries

  • Mexico

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00357123 on ClinicalTrials.gov